KT-621 has demonstrated dupilumab-like activity and was well tolerated in a wide variety of preclinical models of TH2 diseases KT-621 is expected to start Phase 1 in October, with Phase 1 data in the first half of 2025 WATERTOWN, Mass., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced the clearance of its Investigational New Drug (I ...

KT-621 has the potential to provide dupilumab-like activity with an oral small molecule profile for TH2 driven allergic and atopic disease KT-621 demonstrated strong degradation of STAT6 in human sensory neurons resulting in inhibition of IL-13- induced itch- and pain-related gene transcripts with the potential to alleviate these symptoms in atopic dermatitis patients KT-621 expected to start Phase 1 in the second half of 2024, with Phase 1 data in the first half of 2025 WATERTOWN, Mass., Sept. 25, 2024 (GL ...

Core Insights - Kymera Therapeutics reported a narrower loss of 58 cents per share in Q2 2024, better than the expected loss of 69 cents, and improved from a loss of 67 cents per share in the same quarter last year [2][15] - The company experienced a significant increase in collaboration revenues, totaling $25.6 million, which exceeded the consensus estimate of $12 million and represented a 55.3% increase year-over-year [2][3] Financial Performance - Research and development expenses rose to $59.2 million, a 29.3% increase year-over-year, driven by investments in the targeted protein degradation platform and increased occupancy costs [4] - General and administrative expenses increased to $17.4 million, up 22.9% year-over-year, primarily due to higher legal and professional service fees [5] - As of June 30, 2024, the company had $702.4 million in cash and equivalents, expected to last into the first half of 2027, providing a financial cushion for ongoing and upcoming clinical trials [6] Pipeline Developments - Sanofi plans to expand mid-stage studies on KT-474 towards pivotal studies, a first-in-class IRAK4 degrader for immune-inflammatory diseases [7][8] - Kymera is set to initiate a phase I study on KT-621 in the second half of 2024, with data expected in the first half of 2025 [9] - Ongoing phase I studies for KT-253 and KT-333 have shown promising results, with KT-253 demonstrating antitumor activity in various tumor types and KT-333 showing responses in hematological malignancies [11][13][14] Market Position and Outlook - Estimates for Kymera Therapeutics have trended downward, with a consensus estimate shift of -11.79% [15] - The company holds a Zacks Rank of 3 (Hold), indicating expectations for an in-line return in the coming months [17] - In comparison, Denali Therapeutics, a peer in the biomedical industry, has seen a 13.3% gain over the past month, highlighting competitive dynamics within the sector [18]

WATERTOWN, Mass., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced that the Company will participate in fireside chats and presentations at the following upcoming investor events: Wells Fargo 2024 Healthcare Conference in Boston, MA on September 4 at 3:00 p.m. ET; Morgan Stanley 22nd Annual Global Healthcare Conference in New York, ...

Company Overview - Kymera Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing a new class of small molecule medicines using targeted protein degradation (TPD) [5] - The company aims to address critical health problems and improve patients' lives by deploying TPD to target disease pathways that are inaccessible with conventional therapeutics [5] - Kymera has advanced its first degrader into clinical trials for immunological diseases and is also developing oncology programs targeting undrugged or poorly drugged proteins [5] Recent Financial Activity - Kymera Therapeutics announced the closing of an upsized underwritten public offering totaling $225 million, which included common stock and pre-funded warrants [1] - The company sold 2,830,533 shares of common stock at a public offering price of $40.75 per share, along with pre-funded warrants to purchase 3,519,159 shares at a price of $40.7499 each [1] - The gross proceeds from the offering were approximately $258.75 million before deducting underwriting discounts and commissions [1] Underwriters and Regulatory Compliance - Morgan Stanley, J.P. Morgan, TD Cowen, and Stifel acted as joint book-running managers for the offering [2] - The securities were offered under an automatically effective shelf registration statement filed with the U.S. Securities and Exchange Commission (SEC) [3]

Kymera Therapeutics, Inc. (KYMR) announced the pricing of its underwritten public offering of $225 million of shares of its common stock. The company is selling approximately 2 million shares of common stock at a public offering price of $40.75 per share. In addition, it is selling pre-funded warrants to purchase 3.5 million shares in the offering in lieu of common stock to certain investors. The pre-funded warrants are being sold at a public offering price of $40.7499 per pre-funded warrant. This offering ...

WATERTOWN, Mass., Aug. 19, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced the pricing of its underwritten public offering of $225 million of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock. Kymera is selling 2,002,313 shares of common stock and, in lie ...

WATERTOWN, Mass., Aug. 19, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced that it has commenced an underwritten public offering of $200.0 million of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock. All of the shares of common stock and pre-funded warra ...

Kymera Therapeutics, Inc. (KYMR) reported a loss of 58 cents per share in the second quarter of 2024, narrower than the Zacks Consensus Estimate of a loss of 69 cents. In the year-ago quarter, Kymera reported a loss of 67 cents per share. Loss narrowed in the quarter due to higher revenues. Collaboration revenues totaled $25.6 million, which beat the Zacks Consensus Estimate of $12 million. The reported figure increased 55.3% from the year-ago quarter's level. Collaboration revenues in the second quarter we ...

Kymera Therapeutics, Inc. (KYMR) came out with a quarterly loss of $0.58 per share versus the Zacks Consensus Estimate of a loss of $0.69. This compares to loss of $0.67 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 15.94%. A quarter ago, it was expected that this company would post a loss of $0.73 per share when it actually produced a loss of $0.69, delivering a surprise of 5.48%. Over the last four quarters, the company h ...